DnB Asset Management
MRTX

DnB Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

DnB Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,636
Closed -$384K – 677
2023
Q2 		$384K Buy
+10,636
New +$438K ﹤0.01% 644

Other funds holding MRTX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DnB Asset Management's MRTX Position: Q3 2023 in Review

DnB Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2023, closing a stake of 10,636 shares — an estimated $384K sold.

DnB Asset Management first reported a position in MRTX in Q2 2023 and held it in 1 quarter. The position peaked at $384K in Q2 2023. 213 funds tracked by Wall St. Rank hold MRTX as of Q3 2023.

  • DnB Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • DnB Asset Management sold 10,636 Mirati Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $384K.
  • DnB Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • DnB Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $384K in Q2 2023.
  • 213 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2023.

Based on DnB Asset Management's 13F filing for Q3 2023, filed 13 Oct 2023.